DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES

• Main Authors: O´HEAR Carol, Elaine, LI Chi- Chung, BENDER Brendan, Christian
• Format: Patent
• Language: English; Spanish
• Published: 25.05.2023
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab). La presente invención se refiere al tratamiento de sujetos que tienen trastornos proliferativos celulares positivos para CD20 (por ejemplo, trastornos proliferativos de linfocitos B, tales como linfomas no hodgkinianos). Más específicamente, la invención se refiere al tratamiento de sujetos que tienen un trastorno proliferativo de linfocitos B mediante la administración intravenosa de un anticuerpo biespecífico anti-CD20/anti-CD3 (por ejemplo, mosunetuzumab).